Tirzepatide in Metabolic Diseases: Clinical Efficacy and Safety Beyond Diabetes and Obesity
Medicinal Research Reviews · 2026-07 · 46 (4) · 1026-1041
DOI: 10.1002/med.70049 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, online erschienen am 01.04.2026. Verfasst von Shixuan Dong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Institute of Clinical Pharmacy, West China Hospital of Sichuan University, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Tirzepatide, Obesity, Metabolic Diseases, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 124 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Tirzepatide, a novel dual glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) receptor agonist, has attracted substantial attention for its exceptional efficacy in managing type 2 diabetes and obesity. Emerging evidence suggests that tirzepatide may also exert broad therapeutic benefits in cardiovascular diseases, metabolic dysfunction‐associated steatotic liver disease, and chronic kidney disease. However, its potential clinical risks are increasingly being recognized. This review begins by outlining the structural and pharmacological advantages of tirzepatide. We then comprehensively evaluate recent clinical evidence, including randomized controlled trials and real‐world studies, based on a comprehensive literature search, to analyze its efficacy and safety for metabolic disorders. Tirzepatide exhibits considerable promise in treating multiple metabolic diseases; however, its therapeutic benefits must be carefully weighed against potential risks. Conclusions on cardiorenal benefits are supported by high‐level outcome trials, while the evidence for hepatic, renal and musculoskeletal effects is exploratory or preliminary. Further large‐scale, long‐term studies remain essential to fully elucidate its mechanisms of action and overall clinical impact, given the current safety signals and other evidence are largely based on case reports, post hoc analyses, and non‐prespecified endpoints. Continued pharmacovigilance is also crucial to identify and mitigate potential adverse drug reactions in diverse patient populations, especially for rare but serious events identified through spontaneous reporting systems.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Institute of Clinical Pharmacy, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
- West China School of Pharmacy, Sichuan University, Chengdu, Sichuan, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Dong, S., Xu, Y., Gan, R., Zhang, A., He, J., & Tang, Q. (2026). Tirzepatide in Metabolic Diseases: Clinical Efficacy and Safety Beyond Diabetes and Obesity. Medicinal Research Reviews, 46(4), 1026-1041. https://doi.org/10.1002/med.70049
Vancouver
Dong S, Xu Y, Gan R, Zhang A, He J, Tang Q. Tirzepatide in Metabolic Diseases: Clinical Efficacy and Safety Beyond Diabetes and Obesity. Medicinal Research Reviews. 2026;46(4):1026-1041. doi:10.1002/med.70049
BibTeX
@article{Dong2026,
author = {Dong, Shixuan and Xu, Ying and Gan, Ran and Zhang, Ailin and He, Jinhan and Tang, Qin},
title = {Tirzepatide in Metabolic Diseases: Clinical Efficacy and Safety Beyond Diabetes and Obesity},
journal = {Medicinal Research Reviews},
year = {2026},
volume = {46},
number = {4},
pages = {1026--1041},
doi = {10.1002/med.70049}
}
EUVIMED